Clinical trial
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
NCT02876042 · CVRx, Inc., Industry · Unknown status
Key facts
| NCT number | NCT02876042 |
|---|---|
| Title | BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction |
| Official title | BAROSTIM THERAPY ™ in Heart Failure With Preserved Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System |
| Acronym | HFpEF |
| Lead sponsor | CVRx, Inc., Industry |
| Status | Unknown status |
| Study type | Observational [Patient Registry] |
| Conditions | Heart Failure |
| Intervention type | Device |
| Interventions | BAROSTIM NEO™ System |
| Enrollment | 70 |
| Start date | Mar 23, 2017 |
| Primary completion | Jul 1, 2024 |
| Completion | Jul 1, 2024 |
| First posted | Aug 23, 2016 |
| Last update posted | Apr 20, 2023 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: